Intra-Cellular Therapies Quarterly Income Statements Chart
Quarterly
|
Annual
Intra-Cellular Therapies Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | 60,195.5 | 30,754 | 114,741 | 95,287 | 58,201.75 | 4,362 | 228,445 | 15,176.25 | 57,390 | 3,315 | 127,859.75 | 124,414 | 219,238 | 167,787 | 477,367.75 | 667,955 | ||||||||||||||||||||||||||||||
| product sales | 199,223,000 | 175,159,000 | 161,276,000 | 144,843,000 | 131,506,000 | 125,810,000 | 110,128,000 | 94,731,000 | 87,433,000 | 71,870,000 | 55,074,000 | 34,755,000 | 25,516,026 | 21,606,163 | 19,006,780 | 15,578,905 | 12,403,754 | 7,368,594 | 1,875,889 | 882,516 | ||||||||||||||||||||||||||
| grant revenue | 216,000 | 112,000 | 23,000 | 593,000 | 363,000 | 664,000 | 575,000 | 436,000 | 505,000 | 241,000 | 154,900 | 601,038 | 1,039,781 | 299,424 | 50,516 | 30,747 | 200,963 | |||||||||||||||||||||||||||||
| total revenues | 199,223,000 | 175,375,000 | 161,388,000 | 144,866,000 | 132,099,000 | 126,173,000 | 110,792,000 | 95,306,000 | 87,869,000 | 71,870,000 | 55,579,000 | 34,996,000 | 25,670,926 | 22,207,201 | 20,046,561 | 15,878,329 | 12,454,270 | 7,368,594 | 1,906,636 | 1,083,479 | ||||||||||||||||||||||||||
| yoy | 50.81% | 39.00% | 45.67% | 52.00% | 50.34% | 75.56% | 99.34% | 172.33% | 242.29% | 223.63% | 177.25% | 120.40% | 106.12% | 201.38% | 951.41% | 1365.49% | ||||||||||||||||||||||||||||||
| qoq | 13.60% | 8.67% | 11.41% | 9.66% | 4.70% | 13.88% | 16.25% | 8.46% | 22.26% | 29.31% | 58.82% | 36.33% | 15.60% | 10.78% | 26.25% | 27.49% | 69.02% | 286.47% | 75.97% | |||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||
| cost of product sales | 20,405,000 | 15,304,000 | 11,354,000 | 9,900,000 | 10,702,000 | 9,129,000 | 7,163,000 | 6,751,000 | 6,788,000 | 5,850,000 | 4,650,000 | 3,155,000 | 2,538,028 | 2,001,315 | 2,040,031 | 1,455,215 | 1,141,072 | 556,107 | 128,539 | 69,311 | ||||||||||||||||||||||||||
| selling, general and administrative | 137,729,000 | 132,101,000 | 121,574,000 | 113,085,000 | 104,720,000 | 105,207,000 | 101,014,000 | 98,923,000 | 94,631,000 | 88,375,000 | 100,316,000 | 75,460,000 | 79,678,352 | 70,497,885 | 69,851,164 | 52,583,639 | 58,347,948 | 52,473,573 | 41,445,557 | 34,096,366 | ||||||||||||||||||||||||||
| research and development | 70,286,000 | 66,819,000 | 56,183,000 | 42,833,000 | 50,774,000 | 41,550,000 | 49,794,000 | 38,024,000 | 33,862,000 | 33,274,000 | 38,536,000 | 29,043,000 | 29,459,100 | 27,031,825 | 17,296,420 | 15,058,168 | 14,298,586 | 10,275,368 | 25,204,857 | 16,003,326 | 19,065,725 | 21,339,792 | 23,728,464 | 24,990,856 | 33,605,629 | 35,419,016 | 32,439,270 | 30,702,998 | 26,929,041 | 18,472,372 | 12,478,638 | 21,538,958 | 21,179,010 | 23,918,232 | 25,300,668 | 23,433,620 | 22,865,498 | 28,457,631 | 17,762,518 | 18,632,427 | 11,641,009 | 4,046,335 | 2,709,702 | 2,829,299 | 6,129,675 | 4,157,742 |
| total operating expenses | 228,420,000 | 214,224,000 | 189,111,000 | 165,818,000 | 166,196,000 | 155,886,000 | 157,971,000 | 143,698,000 | 135,281,000 | 127,499,000 | 143,502,000 | 107,658,000 | 111,675,480 | 99,531,025 | 89,187,615 | 69,097,022 | 73,787,606 | 63,305,048 | 66,778,953 | 50,169,003 | ||||||||||||||||||||||||||
| income from operations | -29,197,000 | -38,849,000 | -27,723,000 | -20,952,000 | -34,097,000 | -29,713,000 | -47,179,000 | -48,392,000 | -47,412,000 | -55,629,000 | -87,923,000 | -72,662,000 | -86,004,554 | -77,323,824 | -69,141,054 | -53,218,693 | -61,333,336 | -55,936,454 | -64,872,317 | -49,085,524 | -41,768,659 | -36,376,236 | -39,171,114 | -36,695,840 | -42,622,940 | -43,391,345 | -39,168,257 | -37,084,226 | -32,708,264 | -23,759,195 | -18,618,513 | -27,754,157 | -28,032,613 | -30,184,398 | -31,544,027 | -28,497,853 | -29,372,956 | -32,349,375 | -21,690,925 | -22,400,740 | -15,297,070 | -6,503,606 | -4,611,584 | -4,574,463 | -8,032,835 | -4,785,358 |
| yoy | -14.37% | 30.75% | -41.24% | -56.70% | -28.08% | -46.59% | -46.34% | -33.40% | -44.87% | -28.06% | 27.16% | 36.53% | 40.22% | 38.24% | 6.58% | 8.42% | 46.84% | 53.77% | 65.61% | 33.76% | -2.00% | -16.17% | 0.01% | -1.05% | 30.31% | 82.63% | 110.37% | 33.62% | 16.68% | -21.29% | -40.98% | -2.61% | -4.56% | -6.69% | 45.42% | 27.22% | 92.02% | 397.41% | 370.36% | 389.69% | 90.43% | 35.91% | ||||
| qoq | -24.84% | 40.13% | 32.32% | -38.55% | 14.75% | -37.02% | -2.51% | 2.07% | -14.77% | -36.73% | 21.00% | -15.51% | 11.23% | 11.83% | 29.92% | -13.23% | 9.65% | -13.77% | 32.16% | 17.52% | 14.82% | -7.14% | 6.75% | -13.91% | -1.77% | 10.78% | 5.62% | 13.38% | 37.67% | 27.61% | -32.92% | -0.99% | -7.13% | -4.31% | 10.69% | -2.98% | -9.20% | 49.14% | -3.17% | 46.44% | 135.21% | 41.03% | 0.81% | -43.05% | 67.86% | |
| operating margin % | -14.66% | -22.15% | -17.18% | -14.46% | -25.81% | -23.55% | -42.58% | -50.78% | -53.96% | -77.40% | -158.19% | -207.63% | -335.03% | -348.19% | -344.90% | -335.17% | -492.47% | -759.12% | -3402.45% | -4530.36% | ||||||||||||||||||||||||||
| interest income | 11,995,000 | 12,899,000 | 11,560,000 | 6,064,000 | 5,966,000 | 5,498,000 | 4,530,000 | 4,349,000 | 3,386,000 | 2,122,000 | 1,320,000 | 548,000 | 270,617 | 392,695 | 421,028 | 483,750 | -7,826,572 | 752,829 | 1,160,059 | 1,678,203 | -11,396,736 | 1,513,837 | 1,731,550 | 1,860,077 | -12,407,010 | 1,868,431 | 1,793,474 | 1,604,148 | -6,570,611 | 884,763 | 857,809 | 822,175 | -5,065,004 | 763,949 | 709,573 | 656,404 | 540,040 | 188,892 | 179,607 | 113,916 | 99,540 | 88,099 | 80,077 | 36,220 | 18,028 | 5,626 |
| income before benefit from income taxes | -17,202,000 | -25,950,000 | -16,163,000 | -14,888,000 | -28,131,000 | -24,215,000 | -42,649,000 | -44,043,000 | -44,026,000 | -53,507,000 | -86,603,000 | -72,114,000 | -85,733,937 | -76,931,129 | -68,720,026 | -52,734,943 | -60,688,946 | -55,183,625 | -63,712,258 | -47,407,321 | -26,784,431.75 | -34,862,399 | -37,439,564 | -34,835,763 | -28,594,443.75 | -41,522,914 | -37,374,783 | -35,480,078 | -16,891,779.5 | -22,874,432 | -17,760,704 | -26,931,982 | ||||||||||||||
| income tax expense | 317,000 | -374,000 | -57,000 | -359,000 | -448,000 | -43,000 | -135,000 | -10,000 | 5,000 | 23,756 | 5,000 | 10,232 | 3,281 | 400 | 1,600 | 1,600 | 1,600 | 1,898,291 | -832,618 | |||||||||||||||||||||||||||
| net income | -16,885,000 | -26,324,000 | -16,220,000 | -15,247,000 | -28,579,000 | -24,258,000 | -42,784,000 | -44,053,000 | -44,026,000 | -53,508,000 | -86,603,000 | -72,119,000 | -85,733,937 | -76,908,004 | -68,743,782 | -52,739,943 | -60,699,178 | -55,183,625 | -63,712,258 | -47,410,602 | -40,582,851 | -34,862,399 | -37,441,164 | -34,835,763 | -40,748,036 | -41,522,914 | -37,376,383 | -35,480,078 | -30,208,712 | -22,870,416 | -17,760,704 | -26,933,582 | -27,485,039 | -30,265,327 | -30,834,454 | -27,841,449 | -28,834,516 | -32,160,483 | -21,511,318 | -22,286,824 | -15,199,130 | -6,415,507 | -4,533,539 | -4,543,284 | -8,040,810 | -4,911,620 |
| yoy | -40.92% | 8.52% | -62.09% | -65.39% | -35.09% | -54.66% | -50.60% | -38.92% | -48.65% | -30.43% | 25.98% | 36.74% | 41.24% | 39.37% | 7.90% | 11.24% | 49.57% | 58.29% | 70.17% | 36.10% | -0.41% | -16.04% | 0.17% | -1.82% | 34.89% | 81.56% | 110.44% | 31.73% | 9.91% | -24.43% | -42.40% | -3.26% | -4.68% | -5.89% | 43.34% | 24.92% | 89.71% | 401.29% | 374.49% | 390.54% | 89.02% | 30.62% | ||||
| qoq | -35.86% | 62.29% | 6.38% | -46.65% | 17.81% | -43.30% | -2.88% | 0.06% | -17.72% | -38.21% | 20.08% | -15.88% | 11.48% | 11.88% | 30.34% | -13.11% | 9.99% | -13.39% | 34.38% | 16.82% | 16.41% | -6.89% | 7.48% | -14.51% | -1.87% | 11.09% | 5.34% | 17.45% | 32.09% | 28.77% | -34.06% | -2.01% | -9.19% | -1.85% | 10.75% | -3.44% | -10.34% | 49.50% | -3.48% | 46.63% | 136.91% | 41.51% | -0.21% | -43.50% | 63.71% | |
| net income margin % | -8.48% | -15.01% | -10.05% | -10.52% | -21.63% | -19.23% | -38.62% | -46.22% | -50.10% | -74.45% | -155.82% | -206.08% | -333.97% | -346.32% | -342.92% | -332.15% | -487.38% | -748.90% | -3341.61% | -4375.77% | ||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||||
| basic & diluted | -150 | -250 | -160 | -160 | -300 | -250 | -450 | -460 | -460 | -570 | -920 | -780 | -1.06 | -0.95 | -0.85 | -0.65 | -0.75 | -0.79 | -0.96 | -0.73 | -0.74 | -0.63 | -0.68 | -0.63 | -0.75 | -0.76 | -0.68 | -0.65 | -0.56 | -0.53 | -0.41 | -0.62 | -0.63 | -0.7 | -0.71 | -0.64 | -0.66 | -0.91 | -0.61 | -0.72 | -0.52 | -0.22 | -0.15 | -0.17 | ||
| weighted-average number of common shares: | ||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | -1,500 | -1,000 | -1,407.75 | 23,125 | 604 | 4,016 | ||||||||||||||||||||||||||||||||||||||||
| costs and expenses: | ||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 22,763,547 | 15,036,444 | 15,442,650 | 11,704,984 | 9,017,311 | 7,972,329 | 6,728,987 | 6,381,228 | 5,784,278 | 5,317,577 | 6,254,616 | 6,310,486 | 6,951,498 | 6,270,528 | 6,471,804 | 5,064,233 | 6,538,117 | 3,891,744 | 3,985,797 | 3,771,628 | 3,721,923 | 2,581,685 | 2,121,120 | 1,912,951 | 2,730,691 | 1,295,571 | ||||||||||||||||||||
| total costs and expenses | 41,829,272 | 36,376,236 | 39,171,114 | 36,695,840 | 42,622,940 | 43,391,345 | 39,168,257 | 37,084,226 | 32,713,319 | 23,789,949 | 18,733,254 | 27,849,444 | 28,130,508 | 30,188,760 | 31,772,472 | 28,497,853 | 29,403,615 | 32,349,375 | 21,748,315 | 22,404,055 | 15,362,932 | 6,628,020 | 4,830,822 | 4,742,250 | 8,860,366 | 5,453,313 | ||||||||||||||||||||
| income tax (benefit) expense | 400 | |||||||||||||||||||||||||||||||||||||||||||||
| interest expense | 49,041 | -12,260 | -2,032 | -5,041 | -8,003 | -131,888 | ||||||||||||||||||||||||||||||||||||||||
| net income before income tax | -22,027,152.75 | -29,432,709 | ||||||||||||||||||||||||||||||||||||||||||||
| income taxes | ||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||||
| basic | -0.608 | -0.42 | ||||||||||||||||||||||||||||||||||||||||||||
| dilutive | -0.608 | -0.42 | ||||||||||||||||||||||||||||||||||||||||||||
| basic & dilutive | 1,934,312.5 | 11,779,745 |
We provide you with 20 years income statements for Intra-Cellular Therapies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Intra-Cellular Therapies stock. Explore the full financial landscape of Intra-Cellular Therapies stock with our expertly curated income statements.
The information provided in this report about Intra-Cellular Therapies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.